Mangafodipir trisodium injection (Mn-DPDP). A contrast agent for abdominal MR imaging

N. M. Rofsky, J. P. Earls

Research output: Contribution to journalReview articlepeer-review

20 Scopus citations


Mangafodipir trisodium (Mn-DPDP) is one of several recently developed targeted hepatobiliary agents. Contrast-to-noise measurements have shown favorable results for Mn-DPDP-enhanced MR as compared with nonenhanced T1- and T2-weighted images. An improved capability for lesion detection and the ability to characterize tumors of hepatocellular origin have been demonstrated. The prolonged enhancement obtained with Mn-DPDP provides an extended window of time during which effective contrast is maintained as compared with traditional extracellular contrast agents. This report details the experimental and initial clinical experience with Mn-DPDP-enhanced MR imaging of the abdomen.

Original languageEnglish (US)
Pages (from-to)73-85
Number of pages13
JournalMagnetic resonance imaging clinics of North America
Issue number1
StatePublished - Mar 21 1996

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging


Dive into the research topics of 'Mangafodipir trisodium injection (Mn-DPDP). A contrast agent for abdominal MR imaging'. Together they form a unique fingerprint.

Cite this